Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Yao, Jun
Pan, Yu‐qing
Ding, Mei
Pang, Hao
and
Wang, Bao‐jie
2015.
Association between DRD2 (rs1799732 and rs1801028) and ANKK1 (rs1800497) polymorphisms and schizophrenia: A meta‐analysis.
American Journal of Medical Genetics Part B: Neuropsychiatric Genetics,
Vol. 168,
Issue. 1,
p.
1.
Nieuwdorp, Wendy
Koops, Sanne
Somers, Metten
and
Sommer, Iris E.C.
2015.
Transcranial magnetic stimulation, transcranial direct current stimulation and electroconvulsive therapy for medication-resistant psychosis of schizophrenia.
Current Opinion in Psychiatry,
Vol. 28,
Issue. 3,
p.
222.
Jin, Huajie
and
Mosweu, Iris
2017.
The Societal Cost of Schizophrenia: A Systematic Review.
PharmacoEconomics,
Vol. 35,
Issue. 1,
p.
25.
Cheung, Stephane
Hamuro, Yukinobu
Mahlich, Jörg
Nakahara, Takanobu
Sruamsiri, Rosarin
and
Tsukazawa, Sunny
2017.
Drug Utilization of Japanese Patients Diagnosed with Schizophrenia: An Administrative Database Analysis.
Clinical Drug Investigation,
Vol. 37,
Issue. 6,
p.
559.
Mueller-Stierlin, Annabel Sandra
Helmbrecht, Marina Julia
Herder, Katrin
Prinz, Stefanie
Rosenfeld, Nadine
Walendzik, Julia
Holzmann, Marco
Dinc, Uemmueguelsuem
Schützwohl, Matthias
Becker, Thomas
and
Kilian, Reinhold
2017.
Does one size really fit all? The effectiveness of a non-diagnosis-specific integrated mental health care program in Germany in a prospective, parallel-group controlled multi-centre trial.
BMC Psychiatry,
Vol. 17,
Issue. 1,
Laidi, Charles
Prigent, Amélie
Plas, Alice
Leboyer, Marion
Fond, Guillaume
Chevreul, Karine
Aouizerate, B.
Andre, M.
Berna, F.
Capdevielle, D.
Chereau-Boudet, I.
Dorey, J.M.
Dubertret, C.
Dubreucq, J.
Faget, C.
Lancon, C.
Leigner, S.
Llorca, P.M.
Mallet, J.
Misdrahi, D.
Rey, R.
Roux, P.
Schurhoff, F.
Urbach, M.
and
Vidailhet, P.
2018.
Factors associated with direct health care costs in schizophrenia: Results from the FACE-SZ French dataset.
European Neuropsychopharmacology,
Vol. 28,
Issue. 1,
p.
24.
C, Jayakrishnaveni
W.J, Alexander Gnanadura
and
Ravindran, Rekha
2018.
COMPARATIVE STUDY ON THE BURDEN OF BIPOLAR AFFECTIVE DISORDER AND SCHIZOPHRENIA.
Journal of Evidence Based Medicine and Healthcare,
Vol. 5,
Issue. 6,
p.
470.
Kovács, G.
Almási, T.
Millier, A.
Toumi, M.
Horváth, M.
Kóczián, Kristóf
Götze, À
Kaló, Z.
and
Zemplényi, A.T.
2018.
Direct healthcare cost of schizophrenia – European overview.
European Psychiatry,
Vol. 48,
Issue. 1,
p.
79.
Wasserthal, Sven
Kloss, Christian
Hurlemann, René
and
Schultz, Johannes
2018.
N-Acetylcystein: neue Option zur frühen Bekämpfung von Schizophrenie.
DNP - Der Neurologe & Psychiater,
Vol. 19,
Issue. 2,
p.
28.
Fasseeh, A
Németh, B
Molnár, A
Fricke, F-U
Horváth, M
Kóczián, K
Götze, Á
and
Kaló, Z
2018.
A systematic review of the indirect costs of schizophrenia in Europe.
European Journal of Public Health,
Vol. 28,
Issue. 6,
p.
1043.
Zhang, Hui
Sun, Yuming
Zhang, Donglan
Zhang, Chao
and
Chen, Gang
2018.
Direct medical costs for patients with schizophrenia: a 4-year cohort study from health insurance claims data in Guangzhou city, Southern China.
International Journal of Mental Health Systems,
Vol. 12,
Issue. 1,
McNamara, Beverley
Same, Anne
Rosenwax, Lorna
and
Kelly, Brian
2018.
Palliative care for people with schizophrenia: a qualitative study of an under-serviced group in need.
BMC Palliative Care,
Vol. 17,
Issue. 1,
Muntean, Marco
Marinescu, Ileana
Marinescu, Dragoș
Hogea, Lavinia
Suru, Claudia
and
ENĂTESCU, Virgil
2018.
Difficulties in functional recovery in schizophrenia: negative and cognitive symptoms.
Psihiatru.ro,
Vol. 3,
Issue. 54,
p.
30.
Nakamura, Yusuke
Shibata, Isao
and
Mahlich, Jörg
2019.
Modeling the Choice Between Risperidone Long-Acting Injectable and Generic Risperidone from the Perspective of a Japanese Hospital.
Neurology and Therapy,
Vol. 8,
Issue. 2,
p.
433.
Gaebel, Wolfgang
Hasan, Alkomiet
and
Falkai, Peter
2019.
S3-Leitlinie Schizophrenie.
p.
301.
Łaszewska, Agata
Wancata, Johannes
Jahn, Rebecca
and
Simon, Judit
2020.
The excess economic burden of mental disorders: findings from a cross-sectional prevalence survey in Austria.
The European Journal of Health Economics,
Vol. 21,
Issue. 7,
p.
1075.
Xu, Feng-ling
Ding, Mei
Wu, Xue
Liu, Yong-ping
Xia, Xi
Yao, Jun
and
Wang, Bao-jie
2020.
A Meta-analysis of the Association Between SLC6A3 Gene Polymorphisms and Schizophrenia.
Journal of Molecular Neuroscience,
Vol. 70,
Issue. 2,
p.
155.
Hastrup, Lene Halling
Simonsen, Erik
Ibsen, Rikke
Kjellberg, Jacob
and
Jennum, Poul
2020.
Societal Costs of Schizophrenia in Denmark: A Nationwide Matched Controlled Study of Patients and Spouses Before and After Initial Diagnosis.
Schizophrenia Bulletin,
Vol. 46,
Issue. 1,
p.
68.
Vaskova, L. B.
Tiapkina, M. V.
and
Mikhaylenko, E. V.
2020.
Comparative analysis of antipsychotic drug consumption for inpatient schizophrenia treatment: a retrospective study with 5-year follow-up.
FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology,
Vol. 13,
Issue. 3,
p.
251.
Böge, Kerem
Karadza, Almira
Fuchs, Lukas M.
Ehlen, Felicitas
Ta, Thi Minh Tam
Thomas, Neil
Bajbouj, Malek
and
Hahn, Eric
2020.
Mindfulness-Based Interventions for In-Patients With Schizophrenia Spectrum Disorders—A Qualitative Approach.
Frontiers in Psychiatry,
Vol. 11,
Issue. ,
Comments
No Comments have been published for this article.